Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India.

Raina Wadhwa Nidhi Gupta Jyoti Dixit Pankaj MalhotraPvm LakshmiShankar Prinja

Published in: JCO global oncology (2024)

ZA once every 12 weeks is the cost-effective treatment option for BC with bone metastases in India. The present study findings hold significance for standard treatment guidelines under India's government-funded health insurance program.

Keyphrases

health insurance
healthcare
affordable care act
soft tissue
replacement therapy
gestational age
giant cell